Abstract
G protein signaling is an extremely complex event that is involved in almost every cellular process. As such, G protein-coupled receptors are the most commonly found type of transmembrane receptors used by cells to initiate intracellular signaling events. However, the widely accepted model of cyclical GDP-GTP exchange in response to ligand binding to 7TMRs, followed by dissociation of the G protein subunits and activation of intracellular signaling cascades, has repeatedly been challenged in recent years. Some of the exceptions that have been brought forth include signaling by a non-dissociated, rearranged heterotrimer and the existence of “reverse-mode”, active G proteins that interact with active receptors. Here, we focus on Gαi/o, one of the common Gα classes, and outline a major exception to the classical model, that of G protein coupling to RTKs. We then describe a novel concept in Gαi/o signaling, namely that the pathways induced by agonist binding circumvent the typical signaling pathways responsive to decreases in the second messenger cAMP, via adenylyl cyclase inhibition.
Keywords: Adenylyl-cyclase independent, Gαi, G protein-coupled receptors, receptor tyrosine kinase.
Current Vascular Pharmacology
Title:Atypical Gαi Signal Transduction
Volume: 12 Issue: 2
Author(s): Raissa Perrault and Peter Zahradka
Affiliation:
Keywords: Adenylyl-cyclase independent, Gαi, G protein-coupled receptors, receptor tyrosine kinase.
Abstract: G protein signaling is an extremely complex event that is involved in almost every cellular process. As such, G protein-coupled receptors are the most commonly found type of transmembrane receptors used by cells to initiate intracellular signaling events. However, the widely accepted model of cyclical GDP-GTP exchange in response to ligand binding to 7TMRs, followed by dissociation of the G protein subunits and activation of intracellular signaling cascades, has repeatedly been challenged in recent years. Some of the exceptions that have been brought forth include signaling by a non-dissociated, rearranged heterotrimer and the existence of “reverse-mode”, active G proteins that interact with active receptors. Here, we focus on Gαi/o, one of the common Gα classes, and outline a major exception to the classical model, that of G protein coupling to RTKs. We then describe a novel concept in Gαi/o signaling, namely that the pathways induced by agonist binding circumvent the typical signaling pathways responsive to decreases in the second messenger cAMP, via adenylyl cyclase inhibition.
Export Options
About this article
Cite this article as:
Perrault Raissa and Zahradka Peter, Atypical Gαi Signal Transduction, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226122512
DOI https://dx.doi.org/10.2174/1570161112666140226122512 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Nitric Oxide Production during Cerebral Ischemia and Reperfusion in eNOS- and nNOS-Knockout Mice
Current Neurovascular Research Anaemia, Polycythaemia and Chronic Heart Failure
Current Cardiology Reviews Direct Antithrombins: New Perspectives in Cardiovascular Medicine
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Nanocrystal Technology in the Delivery of Poorly Soluble Drugs: An Overview
Current Drug Delivery Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
Current Vascular Pharmacology Regressing Left Ventricular Hypertrophy: The Role of Telmisartan and Other ARBs
Current Hypertension Reviews Targeting Vascular Neural Network in Intracerebral Hemorrhage
Current Pharmaceutical Design Topics on Pharmacology for Dietitians in Modern Practice
Current Nutrition & Food Science Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine Oxidative Stress: Major Threat in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Lipotoxicity and Mitochondrial Dysfunction in Type 2 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A Systematic Review and Meta-Analysis
Current Diabetes Reviews Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals Editorial: Targeting Neuregulin1 and HER Receptor Tyrosine Kinases for Therapy of Breast Cancer and Heart Failure
Current Pharmaceutical Design Therapeutic Perspectives in the Antiphospholipid Syndrome
Current Rheumatology Reviews Trends in the Human Embryonic Stem Cell Patent Field
Recent Patents on Nanotechnology Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets